Document Type
Article
Publication Date
2-13-2018
JAX Source
Oncotarget 2018; 9(8):10497-10509.
PMID
29535822
DOI
https://doi.org/10.18632/oncotarget.24041
Grant
CA127001
Abstract
Background: Despite the availability of hundreds of cancer drugs, there is insufficient data on the efficacy of these drugs on the extremely heterogeneous tumor cell populations of glioblastoma (GBM).
Results: The PKIS of 357 compounds was initially evaluated in 15 different GSC lines which then led to a more focused screening of the 21 most highly active compounds in 11 unique GSC lines using HTS screening for cell viability. We further validated the HTS result with the second-generation PLK1 inhibitor volasertib as a single agent and in combination with ionizing radiation (IR).
Conclusions: Our results reinforce the potential therapeutic efficacy of volasertib in combination with radiation for the treatment of GBM.
Methods: We used high-throughput screening (HTS) to identify drugs, out of 357 compounds in the published Protein Kinase Inhibitor Set, with the greatest efficacy against a panel of glioma stem cells (GSCs), which are representative of the classic cancer genome atlas (TCGA) molecular subtypes.
Oncotarget 2018; 9(8):10497-10509.
Recommended Citation
Dong, Jianwen; Park, Soon Young; Nguyen, Nghi; Ezhilarasan, Ravesanker; Martinez-Ledesma, Emmanuel; Wu, Shaofang; Henry, Verlene; Piao, Yuji; Tiao, Ningyi; Brunell, David; Stephan, Clifford; Verhaak, Roel G W; Sulman, Erik; Balasubramaniyan, Veerakumar; and de Groot, John F, "The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells." (2018). Faculty Research 2018. 53.
https://mouseion.jax.org/stfb2018/53
Comments
This is an open access article under a Creative Commons Attribution 3.0 License.